FDA Orange Book · active-ingredient family
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SYNRIBO · NDA 203585
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SYNRIBORLD | TEVA PHARMS INTL | NDA 203585 | — | Oct 26, 2012 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 6987103 | Oct 26, 2026 | in 4 mo | U-1300 |
Omacetaxine mepesuccinate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
